Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms

Asian Journal of Andrology

Volumn 10, Issue 5, 2008, Pages 777-785

  Noguchi, Masanori ^a   Kakuma, Tatsuyuki ^a   Tomiyasu, Katsuro ^a   Yamada, Akira ^a   Itoh, Kyogo ^a   Konishi, Fumiko ^b   Kumamoto, Shoichiro ^b   Shimizu, Kuniyoshi ^c   Kondo, Ryuichiro ^c   Matsuoka, Kei ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Ganoderma lucidum; Lower urinary tract symptoms; Outcome; Phytotherapy; Randomized trial

Indexed keywords

ALCOHOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; ASCORBIC ACID; AURANTIIN; GANODERMA LUCIDUM EXTRACT; GARDENIA EXTRACT; HERBACEOUS AGENT; MALTITOL; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STARCH; STEROID 5ALPHA REDUCTASE; SUCROSE ESTER DERIVATIVE; TESTOSTERONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD TOXICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDIBLE MUSHROOM; ENZYME ACTIVITY; FATIGUE; HEART RATE; HOARSENESS; HUMAN; HYPERTENSION; IMPOTENCE; INTERNATIONAL PROSTATE SYMPTOM SCORE; LABORATORY TEST; LIVER TOXICITY; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; NAUSEA; NEPHROTOXICITY; NEURALGIA; ORGAN SIZE; PATIENT COMPLIANCE; PHYTOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; URINE FLOW RATE; UROFLOWMETRY;

AGED; DRUGS, CHINESE HERBAL; ETHANOL; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLACEBOS; REISHI; SOLVENTS; TREATMENT OUTCOME; URINATION DISORDERS; URODYNAMICS;

EID: 50149114714     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2008.00361.x     Document Type: Article

References (20)

1. Marwik C. Growing use of medicinal botanicals forces assessment by drug regulators. JAMA 1995; 273: 607-9.
2. Astin JA. Why patients use alternative medicine: Results of a national study. JAMA 1998; 279: 1548-53.
3. Barnes P, Powell-Griner E, McFann K, Nahin R. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004; 343: 1-19.
4. Dreikorn K, Lowe F, Borkowski A, Buck C, Braeckman J, Chopin D, et al. Other medical therapies. In: Chatelain C, Denis L, Foo KT, Khoury S, McConnell J, editors. Proceedings of the 5th International Consultation on Benign Prostatic Hyperpla-sia (BPH). Plymouth: Plymbridge Distributors; 2001.
5. Jenkins EP, Hsieh CL, Milatovich A, Normington K, Berman DM, Francke U, et al. Characterization and chromosomal mapping of a human steroid 5 alpha-reductase gene and pseudogene and mapping of the mouse homologue. Genomics 1991; 11: 1102-12.
6. Iehle C, Radvanyi F, Gil Diez de Medina S, Gerard H, Chopin D, Raynaud JP, et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999; 68: 189-95.
7. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000; 37: 367-80.
8. Uygur MC, Gur E, Arik Al, Altug U, Erol D. Erectile dysfunction following treatments of benign prostatic hyperplasia: A prospective study. Andrologia 1998; 30: 5-10.
9. Liu J, Fujita R, Sato M, Shimizu K, Konishi F, Noda K, et al. The effect of strain, growth stage and cultivating condition of Ganoderma lucidum on 5α-reductase inhibition. J Wood Sci 2005; 51: 189-92.
10. Liang T, Cascieri MA, Cheung AH, Reynolds GF, Rasmusson GH. Species differences in prostatic steroid 5 alpha-reduc-tases of rat, dog, and human. Endocrinology 1985; 117: 571-9.
11. Liu J, Shimizu K, Konishi F, Sato M, Noda K, Kondo R, et al. Anti-androgenic activities of the triterpenoids fraction of Ganoderma lucidum. Food Chem 2007; 100: 1691-6.
12. Yun TK. Update from Asia. Asian studies on cancer chemoprevention. Ann NY Acad Sci 1999; 889: 157-92.
13. Noguchi M, Kakuma T, Tomiyasu K, Konishi F, Kumamoto S, Kondo R, et al. Phase I study of an ethanol extract of Ganoderma lucidum, edible and medicinal mushroom, in men with mild symptoms of bladder outlet obstruction. Asian J Androl, in press.
14. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtqrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-57.
15. Descotes JL, Rambeaud JJ, Deschaseaux P, Faure G. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995; 9: 291-7.
16. Cukier J, Ducassou J, Le Guillou M. Permixon versus placebo: Results d'une etude multicentrique. C R Ther Pharmacol Clin 1985; 4: 15-21.
17. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006; 354: 557-66.
18. Boyle P, Robertson C, Lowe F, Roehrbom C. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000; 55: 533-9.
19. Hruby S, Djavan B, Reissigl A, Chaudr A, Alavi S, Anagnostou T, et al. Progression delay in men with mild symptoms of bladder outlet obstruction: A prospective comparative study of phytotherapy, watchful waiting and placebo. J Urol 2003; 169 (Suppl): 332.
20. Berges R, Hofner K. Drug therapy for benign prostatic hyperplasia: A systemtic overview. Urologe A 2005; 44: 505-12.